Development Delay, Refractory Epilepsy
Conditions
Keywords
Observational, Retrospective
Brief summary
This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review).
Detailed description
This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review). The identified local site staff (or trained independent data abstractors, if requested by the site) will review the medical records of all participants meeting the eligibility criteria, who have provided a signed inform consent form (ICF) for data collection and analysis. For participants who are less than 18 years of age, in addition to the assent form being signed by the participant, an informed consent would be obtained from parental or legally authorized representative. In line with the retrospective nature of the study: there is no assignment of a participant to a particular therapeutic strategy; no additional diagnostic or monitoring procedures shall be applied to the participants; epidemiological methods shall be used for the analysis of collected data; the prescription of any medication for the treatment of the epileptic syndrome occur before the collection of the data in this study and is clearly separated from the decision to include the participant in the study.
Interventions
None listed
Sponsors
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Zogenix, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥2 years * Disease history of at least 24 months from date of first seizure * Medical history of epilepsy associated with moderate to severe intellectual disability, cognitive developmental delay or cognitive regression * Medical history of onset of seizures in early childhood (≤ 8 years) * Failure of adequate trials of two tolerated and appropriately chosen and used Anti-Epileptic Drug (AED) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom * Ongoing refractory epilepsy * MRI and EEG data are available for the participant * Participants (or their parents/ legal representative as appropriate) have provided written informed consent / assent form to collect the data specified.
Exclusion criteria
* Normal cognitive development. * Any acute symptomatic seizures in participants with underlying developmental delay. * Any progressive intellectual and neurological deterioration conditions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With and Without Diagnosis of an Epilepsy Syndrome | 5 months | Understand the proportion of participants with and without diagnosis of an epilepsy syndrome, as described by the International League Against Epilepsy (ILAE) diagnostic manual located at https://www.epilepsydiagnosis.org/ |
| Understand the Clinical Practice Criteria | 5 months | Understand the clinical practice criteria used for specific syndromic diagnosis of participants with refractory epilepsy associated with developmental delay. |
| Clinical Practice Diagnostic Criteria Compared to ILAE | 5 months | Compare clinical practice diagnostic criteria to those proposed by the ILAE and identify potential areas of educational need. |
| Understand the Time to Formal Diagnosis | 5 months | Understand the time to diagnosis, from first seizure to formal diagnosis of a specific syndrome. |
| Unclassified Epilepsy | 5 months | Evaluate if unclassified epilepsy can be grouped with common electroclinical phenotype features. |
Countries
France, Germany, Italy, Spain
Outcome results
None listed